Palak Kachhadia
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1003299389
Payments from drug & device makers
Across 98 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$332
- Novo Nordisk$256
- AstraZeneca$218
- Amgen$191
- Boehringer Ingelheim$144
- Sanofi-aventis U.S. LLC$142
- plus $846 from 19 others
What the payments were for
- Food & beverage$2,123100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 15 | $332 |
| Novo Nordisk | 18 | $256 |
| AstraZeneca(2 entities) | 9 | $218 |
| Amgen(2 entities) | 4 | $191 |
| Boehringer Ingelheim | 10 | $144 |
| Sanofi-aventis U.S. LLC | 6 | $142 |
| Corcept Therapeutics | 1 | $120 |
| Sequel Med Tech, LLC | 1 | $118 |
| AbbVie(2 entities) | 5 | $82 |
| Tandem Diabetes Care, Inc. | 1 | $75 |
| Mannkind Corporation | 1 | $65 |
| GSK | 4 | $56 |
| Merck | 4 | $47 |
| Insulet Corporation | 3 | $45 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Globus Medical | 1 | $27 |
| Ironwood Pharmaceuticals, Inc | 2 | $27 |
| Genentech USA, Inc. | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $23 |
| Abbott | 1 | $22 |
| Saluda Medical Americas, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,129 in reported general payments places this provider in the 20th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $76,823 |
| MounjaroTirzepatide | 52 | $56,158 |
| TrulicityDulaglutide | 29 | $51,642 |
| JardianceEmpagliflozin | 30 | $33,137 |
| RybelsusSemaglutide | 13 | $22,272 |
| NovologInsulin Aspart | 11 | $3,537 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,076 |
| TirosintLevothyroxine Sodium | 11 | $1,493 |
| Levothyroxine Sodium | 108 | $1,274 |
| Metformin Hcl ErMetformin Hcl | 42 | $1,123 |
| Hydrocortisone | 19 | $730 |
| Ezetimibe | 12 | $423 |
| Metformin Hcl | 19 | $254 |
| Prednisone | 13 | $210 |
| Atorvastatin Calcium | 16 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $332 | $107,80081 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $256 | $102,63379 claims |
| Boehringer IngelheimJardiance | $144 | $33,13730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- William GarveyBirmingham$3.8M
- Fernando OvalleBirmingham$516K
- Ralph TeagueBirmingham$487K
- Amy WarrinerBirmingham$182K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Tom VaughanBirmingham$68K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.